Taken together, our data confirm that externally administered cysteine proteases CTSB and CTSL promote the clearance of SNCA species in vitro, ex vivo as well as in vivo, providing a new therapeutic approach for the treatment of synucleinopathies. The gene discussed is CTSL; the disease is synucleinopathy.